Champions Biotechnology and PinnacleCare sign collaboration agreement

Champions Biotechnology, a provider of personalized oncology services, has entered into a personalized oncology collaboration agreement with PinnacleCare, a health advisory company.

PinnacleCare will offer Champions Biotechnology's personalized oncology services to its members worldwide who have been diagnosed with cancer. Access to Champions Biotechnology's services will benefit PinnacleCare members, and their physicians, in evaluating personalized options to improve treatment outcomes.

Champions Biotechnology's services offered to PinnacleCare members will include: Personalized Oncology Panels comprised of experts assembled to assist the client's physician in determining the optimal treatment, and Personalized Tumorgrafts developed from fragments of the client's living tumor that are surgically removed, propagated and tested to evaluate the effectiveness of potential treatment drugs.

Through this collaboration, Champions Biotechnology will also offer PinnacleCare's health advisory services to Champions clients. These services include a PinnacleCare health advisor available globally and 24/7 answering client questions, coordinating healthcare schedules, explaining options, arranging treatments, assisting with individual medical experts, staff, and bureaucracies, and available to attend important appointments.

These services also include a PinnacleCare Electronic Health Records including collection, organization, and physician review of client medical records, with all records kept up-to-date and available instantly anywhere in the world for the client and his/her expert healthcare team.

Miles Varn, chief medical officer of PinnacleCare, said: "Champions Personalized Oncology Panels and its Personalized Tumorgraft technology are exactly the kind of cutting edge programs that PinnacleCare seeks for its members.

"We believe that the Champions approach to personalized oncology will be of great benefit to our current and prospective members through programs that evaluate treatment options based on the very unique characteristics of each patient's cancer."

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Related terms: advisor, biotechnology, cancer, drugs, health, healthcare, medical, physicians, technology